news
Nanoparticle COVID-19 vaccine shows promise in pre-clinical trials
A new nanoparticle-based vaccine has demonstrated success in ferret models of COVID-19, inducing strong neutralising antibodies against SARS-CoV-2.
List view / Grid view
Covid-19
news
In silico screening of existing drugs reveals three candidates against SARS-CoV-2
A novel in silico approach applied to drug screening has revealed three potential candidates that may interact with multiple proteins of SARS‐CoV‐2.
news
Balanced T-cell response key to asymptomatic COVID-19, study suggests
A new study has suggested that asymptomatic individuals with COVID-19 mount an efficient T-cell response that protects the host.
news
Screening by compound activity could accelerate drug discovery
Researchers have developed a new screening technique called biological activity-based modelling to identify drug candidates.
video
SARS-CoV-2 vaccines: an interview with Payton Weidenbacher
DTR's Victoria Rees interviews Payton Weidenbacher from Stanford University, who discusses a new potential SARS-CoV-2 vaccine that the team he works on developed using nanotechnology.
news
SARS-CoV-2 model shows Spike protein co-operation
A new coarse-grained model of the complete SARS-CoV-2 virion has revealed potential new ways to combat the coronavirus.
news
Scientists uncover structural biology details of SARS-CoV-2 infection
Researchers have used computer simulations to model how the SARS-CoV-2 fusion peptide interacts with and penetrates the cell membrane.
news
Lung and brain organoids respond differently to SARS-CoV-2 infection in lab
Researchers have developed stem cell-derived organoids to reveal how SARS-CoV-2 interacts with lung and brain cells differently.
news
Over 87,000 papers published on coronavirus since start of pandemic
Between January and October 2020, scientists globally have published more than 87,000 papers about the coronavirus.
news
Screening of approved drugs reveals potential treatment for COVID-19
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
news
Researchers identify new therapeutic targets on SARS-CoV-2 Spike protein
Researchers have found that the S1/S2 cleavage of the SARS-CoV-2 Spike protein could be a potential target for COVID-19 therapeutics.
news
UK Government to fund four studies investigating long COVID
The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
news
D614G Spike mutation makes SARS-CoV-2 up to eight times more infectious
A study has shown the D614G mutation in the Spike protein of SARS-CoV-2 makes the coronavirus more transmissible than the original virus from China.
news
Engineered peptide protects ferrets against SARS-CoV-2 transmission, study shows
A peptide administered to ferrets protected them from SARS-CoV-2 viral transmission when housed with infected ferrets.
article
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
